6 completed, 2 recruiting, 1 unknown, 1 withdrawn. 10 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 6, Recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 2, Recruiting 2, Unknown 1, Withdrawn 1 |
Follow nitazoxanide: new trials by email Literature Review of nitazoxanide trials Research Report on nitazoxanide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nitazoxanide in Spontaneous Bacterial Peritonitis Nitazoxanide (NTZ), Placebo - SBP - Spontaneous Bacterial Peritonitis | Phase 1 / Phase 2 | Recruiting | Tanta University | 60 | 2026-10-25 | 2026-10-30 |
| Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation Nitazoxanide 500Mg Oral Tablet, Rifaximin 550Mg Tab - Irritable Bowel Syndrome With Diarrhea | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2022-07-01 | 2025-07-14 | |
| Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects Nitazoxanide - Renal Impairment, Renal Disease | Phase 1 | Completed | Genfit | 77 | 2022-04-25 | 2022-10-28 |
| Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients Nitazoxanide - Moderate Hepatic Impairment, Severe Hepatic Impairment | Phase 1 | Completed | Genfit | 25 | 2021-11-05 | 2022-10-14 |
| AGILE (Early Phase Platform Trial for COVID-19) CST-2: EIDD-2801, CST-2: Placebo, Nitazoxanide - Covid19 | Phase 1 / Phase 2 | Recruiting | University of Liverpool | 600 | 2020-07-03 | 2026-06-01 |
| Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis parasitological diagnostics (coproscopy), Nitazoxanide 500Mg Oral Tablet, Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet - Ulcerative Colitis, Ulcerative Colitis Exacerbation | Phase 1 / Phase 2 | Unknown | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | 300 | 2015-01-01 | 2023-03-03 |
| A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures Nitazoxanide With Pegylated Interferon And Ribavirin - Hepatitis C Infection, HIV Infection | Phase 1 / Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 8 | 2010-08-01 | 2021-10-05 |
| A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation Nitazoxanide - Hepatitis C Recurrence | Phase 1 | Completed | Mayo Clinic | 8 | 2009-02-01 | 2012-07-31 |
| A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea Nitazoxanide - HIV Infections | Phase 1 | Completed | Unimed Pharmaceuticals | 28 | 1995-10-01 | 2005-06-24 |
| Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children Nitazoxanide - HIV Infections, Cryptosporidiosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 6 | 2021-11-01 |
HIV Infections (3) · AIDS-Related Opportunistic Infections (1) · COVID-19 (1) · Colitis, Ulcerative (1) · Cryptosporidiosis (1) · Hepatitis C (1) · Kidney Diseases (1) · Liver Diseases (1) · Protozoan Infections (1) · Renal Insufficiency (1) · Trematode Infections (1)
Genfit (2) · Mayo Clinic (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institutes of Health Clinical Center (CC) (1) · Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan (1) · Sadat City University (1) · Tanta University (1) · Unimed Pharmaceuticals (1) · University of Liverpool (1)
United States (5) · Egypt (2) · South Africa (2) · Thailand (1) · United Kingdom (1)
Carol Addy, MD (2) · Myron Levin, MD (1) · Rosemary Soave (1) · Saye Khoo (1) · Shyamasundaran Kotilil, M.D. (1) · W Ray Kim, MD (1)
PMID 30251569, PMID 33188747, PMID 34450619, PMID 34473343, PMID 34699618, PMID 35271729, PMID 36272432, PMID 36435798, PMID 41848748